在肿瘤治疗领域不断探索与创新的征程中,港股上市企业美中嘉和(02453.HK)凭借质子治疗技术的成功应用,正稳步提升其在国际舞台上的影响力。2025 年 1 月,美中嘉和旗下的广州泰和肿瘤医院质子中心首批患者顺利结束治疗,患者疾病类型涵盖肺癌、鼻咽癌、头颈部肿瘤、乳腺癌、前列腺癌、食管癌、胰腺癌以及骨肉瘤等多种恶性肿瘤。值得关注的是,该院质子治疗的咨询者来源广泛,不仅有中国大陆各地及香港特别行政区...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.